[´º½º·±=¼Ò¹ÎÈñ ±âÀÚ]
¿À½ºÆ®¸®¾Æ ºñ¿£³ª¿¡¼ °³ÃÖµÈ 2018À¯·´ Å©·Ðº´ ¹× ´ëÀå¿°ÇÐȸ(ECCO: Congress of the European Crohn’s and Colitis Organization)[1]¿¡¼ Å©·Ðº´ ȯÀÚ ´ë»óÀÇ ´ë±Ô¸ð Àӻ󿬱¸ °á°ú°¡ °ø°³µÆ´Ù.
¿¬±¸¿¡¼ ·¥½Ã¸¶··¹¹ÌÄÉÀ̵å·ÈÞ¹Ì¶ó¸¦ Åõ¿©¹ÞÀº ȯÀÚµéÀÇ 54ÁÖÂ÷ °üÇØÀ²(Remission Rate)Àº 39.0%·39.7%·32.7%·Î, °¢ ±º°£ µ¿µîÇÑ ¼öÁØÀÇ È¿´ÉÀÌ ³ªÅ¸³µ´Ù.
¿µ±¹ ·Î¾â µ¥º» ¿¢¼ÅÍ º´¿ø(Royal Devon and Exeter Hospital) ¼Òȱ⳻°ú Àü¹®ÀÇ ´ÏÄÝ¶ó½º Äɳ׵ð(Nicholas Kennedy) ¹Ú»ç´Â 17ÀÏ(ÇöÁö½Ã°£) ÁøÇàµÈ ÇÐȸ ±¸¼ú¹ßÇ¥(Oral Presentation) ¼¼¼Ç¿¡¼ Å©·Ðº´ ȯÀÚº° ¸ÂÃã Ä¡·á ÀÓ»ó(PANTS Study, Personalised Anti-TNF Therapy in Crohn’s disease Study) °á°ú¸¦ ¹ßÇ¥Çß´Ù.
ÀÓ»óÀº ¿µ±¹ ±¹¸³°Ç°¿¬±¸¿ø ¿¢¼ÅÍ Àӻ󿬱¸±â°ü(NIHR Exeter Clinical Research Facility)[2]¿¡ ÀÇÇØ ¿µ±¹ Àü¿ª 118°³ º´¿ø¿¡¼ ÃÑ 1,610¸íÀÇ ½ÇÁ¦ ȯÀÚ¸¦ ´ë»óÀ¸·Î 3³â¿¡ °ÉÄ£ ÀüÇâÀû °üÂû¿¬±¸(three-year prospective observational study)·Î ÁøÇàµÆ´Ù.
ÀÇ·áÁøÀº ·¥½Ã¸¶, ·¹¹ÌÄÉÀ̵å, ÈÞ¹Ì¶ó¸¦ Åõ¿©¹Þ´Â ȯÀÚµéÀÇ Ç÷Á߾๰³óµµ ¸ð´ÏÅ͸µ(TDM, Therapeutic Drug Monitoring)À» ÅëÇØ ³ªÅ¸³ ¾à¹°µ¿·ÂÇÐ(Pharmacokinetics) ¹× ¾à¹°¿¡ ´ëÇÑ Ç×ü(Anti-drug antibody) °á°ú¿¡ µû¶ó 12°³¿ù °£ÀÇ Ä¡·á µ¥ÀÌÅ͸¦ ºÐ¼®ÇØ È¯ÀÚÀÇ ÃÖÃʹ«¹ÝÀÀ(PNR, Primary Non-Response), ¹ÝÀÀ¼Õ½Ç(LOR, Loss of Response) ¹× ºÎÀÛ¿ë(ADR, Adverse Drug Reaction)À» Á¶»çÇß´Ù.
´ÏÄÝ¶ó½º Äɳ׵ð ¹Ú»ç´Â ¹ßÇ¥¿¡¼ “À̹ø ¿¬±¸·Î ¿°Áõ¼º ÀåÁúȯ ȯÀÚÀÇ TNF¾ËÆľïÁ¦Á¦ Ä¡·á¿¡¼ ¾à¹° È¿°ú¸¦ ÃÖÀûÈÇÏ°í, Ä¡·á ½ÇÆи¦ ¿¹¹æÇϱâ À§ÇÑ ±âȸ¸¦ È®ÀÎÇß´Ù”¸ç “¿ì¸®´Â ÀÌ ¿¬±¸°¡ ȯÀÚÀÇ ÇýÅÃÀ» ÃÖ´ëÈÇϱâ À§ÇÑ Ä¡·á Àü·«°ú È¿°úÀûÀÎ ºñ¿ëÀÇ Ä¡·áÀü·«À» ¹ßÀü½ÃÅ°´Â Áß¿äÇÑ ¿¬±¸°¡ µÉ °ÍÀ¸·Î ¹Ï´Â´Ù”°í ¸»Çß´Ù.
¼¿Æ®¸®¿Â °ü°èÀÚ´Â “ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ·¥½Ã¸¶¸¦ ÅëÇØ È¯ÀÚ °³Àο¡ ÃÖÀûÈµÈ ¸ÂÃã Ä¡·á ±âȸ¸¦ Á¦°øÇÔÀ¸·Î½á ȯÀÚµéÀÇ Ä¡·á È¿°ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ°í, Áú ³ôÀº ÀÇ·á ¼ºñ½º°¡ Á¦°øµÉ ¼ö Àֱ⸦ ±â´ëÇÑ´Ù”¸ç “´õ ¸¹Àº ȯÀÚ°¡ ¸ÂÃã Ä¡·á¿¡ Á¢±Ù ÇÒ ¼ö ÀÖµµ·Ï ¾àµ¿ÇÐ ¸ð´ÏÅ͸µ Å°Æ®¿Í °°Àº Çõ½Å ±â¼úÀ» Áö¼ÓÀûÀ¸·Î ¹ßÀü½ÃÄÑ ³ª°¥ °èȹÀÌ´Ù”¶ó°í µ¡ºÙ¿´´Ù.
¼Ò¹ÎÈñ ±âÀÚ news114 @newsrun.co.kr
¼Ò¹ÎÈñ ±âÀÚ news114 @newsrun.co.kr
<ÀúÀÛ±ÇÀÚ © ´º½º·±, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>